Patient Support

Resources to help your patients manage out-of-pocket expenses for FYCOMPA®, including information about Eisai Assistance Program and the FYCOMPA® Patient Assistance Program.

Eisai Assistance Program

The Eisai Assistance Program provides information to patients and healthcare professionals regarding the patient’s insurance benefits for coverage of FYCOMPA®. In addition, our agents can also provide information relating to payor-specific policies for the coverage of FYCOMPA®, information regarding billing and coding requirements, and answer questions regarding financial assistance options. Call the Eisai Assistance Program today for all of your billing, coding, coverage, and financial assistance questions.

Contact Us

Eisai Assistance Program

Phone: 1-855-EISAI-4-U (1-855-347-2448)
Fax: 1-800-226-2059
Monday – Friday, 8 am to 5 pm ET

FYCOMPA® Instant Savings Card Program*

Important Update For Your Patients Taking or Considering Fycompa
The FYCOMPA Co-pay Program now covers UP TO $1300 PER YEAR

The Instant Savings Card Program helps your patients save in two ways:

  • With the FYCOMPA® Instant Savings Card, patients with prescription coverage and a copayment of more than $10 may be eligible to receive out of pocket support. Your eligible patient will pay no more than $10 for his/her FYCOMPA® co-pay, and Eisai will pay the remaining out-of-pocket expense up to $1,300 a year. Patients without prescription coverage may receive up to $60 off their FYCOMPA® prescription up to $720 a year.
  • Eligible patients could have additional financial responsibility for any amounts over Eisai's maximum liability.

Who's Eligible for Savings?

This offer is available to commercially insured patients and patients without insurance. This offer is not available to patients enrolled in a state or federal healthcare program, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE. If you have any questions regarding your patient's eligibility or if you wish for your patient to discontinue participation, call the FYCOMPA® Assistance Program at 1-855-347-2448 (9:00 AM - 5:00 PM ET Monday - Friday).

Register online to Activate Savings

To receive an Instant Savings Card, your patient must register for the program. Please click here to register online, or call The FYCOMPA® Assistance Program at 1-855-347-2448 (9:00 AM - 5:00 PM ET Monday—Friday) to register.

*Restrictions and Conditions of Use for the Instant Savings Card Program

  • Good toward the purchase of FYCOMPA® prescriptions.
  • No substitutions permitted.
  • Save this card to reuse with each prescription.
  • Not available to patients enrolled in Federal or state healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE.
  • Offer available to MA residents through July 1, 2019.
  • May not be combined with any other discount or offer.
  • Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card.
  • Void outside the USA and where prohibited by law.
  • Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice.
  • Must be 12 years of age or older.
  • Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying with any other conditions imposed by insurance carriers, third-party payers, and applicable law on the redemption.
  • The value of this card is not contingent on any prior or future purchases.
  • This card may not be accepted at all pharmacies.
  • Not valid for prescriptions for FYCOMPA® or any other product reimbursed in full by third-party payers.
  • This card is not an insurance program.
  • No membership fees.
  • This offer will expire July 1, 2019.

FYCOMPA® Patient Assistance Program

Eisai has created the FYCOMPA® Patient Assistance Program for customers who need assistance paying for FYCOMPA®. This program provides FYCOMPA® at no or low cost to financially needy patients who meet program eligibility criteria.

Healthcare providers can call the FYCOMPA® Patient Assistance Program at 1-855-EISAI-4-U (1-855-347-2448). Hours of operation are Monday to Friday 8 am to 5 pm ET.

Eisai reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends upon availability.

Find Information on Medicare Coverage

Learn about coverage alternatives for FYCOMPA® including Medicare coverage

Get dose recommendations for introduction of FYCOMPA®

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

+ Expand - Collapse



  • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA
  • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression
  • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA
  • Closely monitor patients particularly during the titration period and at higher doses
  • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening


In the partial-onset seizures clinical trials, hostility- and aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in FYCOMPA-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. Homicidal ideation and/or threat have also been reported postmarketing in patients treated with FYCOMPA. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Similar serious psychiatric and behavioral events were observed in the primary generalized tonic-clonic (PGTC) seizure clinical trial.


Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm and/or any unusual changes in mood or behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.


FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial.


FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events. Somnolence was reported in 16% and 18% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and 15% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 5% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known.


Falls were reported in 5% and 10% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 3% of placebo-treated patients.


DRESS, also known as multiorgan hypersensitivity, has been reported in patients taking AEDs, including FYCOMPA. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement. If signs or symptoms are present, immediately evaluate the patient and discontinue FYCOMPA if an alternative etiology for signs or symptoms cannot be established.


A gradual withdrawal is generally recommended with AEDs to minimize the potential of increased seizure frequency, but if withdrawal is a response to adverse events, prompt withdrawal can be considered.


The most common adverse reactions in patients aged 12 years and older receiving FYCOMPA (≥5% and ≥1% higher than placebo) include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, and anxiety. Adverse reactions in patients aged 4 to <12 years were generally similar to patients aged 12 years and older.


FYCOMPA may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of perampanel were decreased when administered with known moderate and strong CYP3A4 inducers, including, carbamazepine, phenytoin, or oxcarbazepine. Multiple dosing of FYCOMPA 12 mg per day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants.


Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when FYCOMPA is administered to pregnant or nursing women as there are no adequate data on the developmental risk associated with use in pregnant women, and no data on the presence of perampanel in human milk, the effects on the breastfed child, or the effects of the drug on milk production.


Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment.


FYCOMPA is a Schedule III controlled substance and has the potential to be abused and lead to drug dependence and withdrawal symptoms including anxiety, nervousness, irritability, fatigue, asthenia, mood swings, and insomnia.


FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial-onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic-clonic (PGTC) seizures.

View the Prescribing Information.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.

FYCOMPA® is a trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc. Manufactured and Marketed by Eisai, Inc., Woodcliff Lake, NJ 07677.